-- Racura Oncology (ASX:RAC) said it ended the fiscal third quarter with a cash balance of about AU$19.4 million and is in a strong position to finance activities through 2027, according to a Thursday filing with the Australian bourse.
The early conversion of options gave the company an additional AU$1.4 million of funding, per the filing.
Racura Oncology said more than 81% of spending during the March quarter, or about AU$2.4 million, went toward research and development and drug manufacturing activities.